Eight Roads Ventures

Eight Roads Ventures is a global venture capital firm and the proprietary investment arm of Fidelity International Limited. With offices in London, Hong Kong, Beijing, Shanghai, Tokyo, Mumbai, and other locations, it invests across Europe, Asia, and North America in technology-driven companies. The firm targets sectors including software and services, healthcare IT, information technology, FinTech, consumer and enterprise technology, e-commerce, and real estate tech linked to data. It backs start-ups and growth-stage companies from early to late stages, often leading rounds and, when appropriate, co-investing with other top firms; it seeks board seats in portfolio companies. Eight Roads manages about $11 billion in assets and has a five-decade history of supporting hundreds of companies worldwide, reflecting a track record across technology, health tech and related fields.

Umang Agarwal

Principal

Hiroki Ashida

Vice President

Daniel Auerbach

Senior Managing Partner, Asia

Vytautas Balsys

Partner

Helena Barman

Investor

Past deals in Hong Kong

Jade Bird Display

Series A in 2022
Jade Bird Display (Shanghai) Limited is a manufacturer based in Shanghai, China, specializing in the development and production of micro-LED display chips and panels. Founded in 2015, the company focuses on research and development to create the smallest, brightest, and most efficient micro-display solutions. Its products are designed for various applications, including augmented reality (AR), virtual reality (VR), head-up displays (HUD), projectors, weapon sights, 3D printing, and microscopes. By providing ultra-compact micro-display panels, Jade Bird Display enables original equipment manufacturers to enhance user experience in AR and VR hardware, offering improved comfort, outdoor readability, and extended operating times between charges. The company also maintains an office in Hong Kong to support its operations.

Innovent Biologics

Series C in 2015
Innovent Biologics is a China-based biopharmaceutical company that discovers, develops, manufactures, and commercializes monoclonal antibodies. It operates a platform for antibody therapeutics across oncology, ophthalmology, immunology, and metabolic diseases, with Tyvyt (sintilimab) as its core asset, a PD-1 inhibitor used in first-line and other cancer indications. The company develops a broad pipeline including biosimilars and novel antibodies and provides distribution, consulting, and R&D services. It maintains strategic collaborations with global partners, including a co-development arrangement with MD Anderson Cancer Center and an alliance with Eli Lilly for TYVYT, and has more than 30 collaborations with major pharmaceutical companies. Innovent is listed on the Hong Kong Exchange and maintains manufacturing and development capabilities in China with a growing portfolio of oncology and non-oncology products marketed domestically and internationally.

Innovent Biologics

Series B in 2012
Innovent Biologics is a China-based biopharmaceutical company that discovers, develops, manufactures, and commercializes monoclonal antibodies. It operates a platform for antibody therapeutics across oncology, ophthalmology, immunology, and metabolic diseases, with Tyvyt (sintilimab) as its core asset, a PD-1 inhibitor used in first-line and other cancer indications. The company develops a broad pipeline including biosimilars and novel antibodies and provides distribution, consulting, and R&D services. It maintains strategic collaborations with global partners, including a co-development arrangement with MD Anderson Cancer Center and an alliance with Eli Lilly for TYVYT, and has more than 30 collaborations with major pharmaceutical companies. Innovent is listed on the Hong Kong Exchange and maintains manufacturing and development capabilities in China with a growing portfolio of oncology and non-oncology products marketed domestically and internationally.

Wisers Information

Venture Round in 2008
Wisers Information Limited, established in 1998 and headquartered in Wan Chai, Hong Kong, is a leading provider of Chinese media and business intelligence solutions. The company specializes in a wide range of services, including enterprise search, media and social intelligence, and financial and risk intelligence, catering to various sectors such as education, luxury and retail, government, and information technology. Wisers aggregates data from diverse media sources, including online platforms, social media, print, and broadcast media, enabling clients to access crucial insights for decision-making. Its offerings include WiseSearch, a database tailored for Chinese markets, WiseSocial for social listening, and solutions for risk management and competitive analysis. The company serves a diverse clientele, including local blue-chip firms, Fortune 500 companies, international banks, and governmental organizations across China and the Hong Kong Special Administrative Region, supporting their need for actionable intelligence and market understanding. Additionally, Wisers maintains a presence in major cities such as Beijing, Guangzhou, and Shanghai, enhancing its ability to serve clients effectively.

Picsolve

Venture Round in 2008
Picsolve specializes in image capture solutions for the leisure and entertainment industry, boasting over 20 years of experience in the field. With a global presence in the UK, UAE, USA, and Hong Kong, the company offers comprehensive services that ensure efficient operations across various locations. Picsolve's approach combines retail expertise with advanced technology and innovative strategies, all aimed at enhancing guest experiences. By focusing on delivering high-quality image capture, the company plays a significant role in enriching visitor engagement in theme parks, attractions, and other entertainment venues.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.